Analysis of pramipexole dose–response relationships in Parkinson’s disease

BACKGROUND: Pramipexole (PPX), a non-ergot dopamine receptor agonist, is a first-line treatment for Parkinson’s disease (PD). A critical dose level above which a better benefit-to-harm ratio exists has not been examined. METHODS: Chinese PD patients (n=464) were retrospectively analyzed by PPX maint...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ying, Sun, Sheng-Gang, Zhu, Sui-Qiang, Liu, Chun-Feng, Liu, Yi-Ming, Di, Qing, Shang, Hui-Fang, Ren, Yan, Xiang, Wei, Chen, Sheng-Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207331/
https://www.ncbi.nlm.nih.gov/pubmed/28096656
http://dx.doi.org/10.2147/DDDT.S112723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207331/
https://www.ncbi.nlm.nih.gov/pubmed/28096656
http://dx.doi.org/10.2147/DDDT.S112723

Ejemplares similares